![OptiScan Imaging Limited ABN 81 077 771 987]

ASX Announcement

7 November 2018

ZEISS achieves another milestone on regulatory pathway

Carl Zeiss Meditec AG (CZM) has informed Optiscan Imaging Limited (**OIL** or **Optiscan**) that it has achieved another milestone on its regulatory pathway with FDA clearance and is progressing as planned with full commercialization of CONVIVO.

At this time, there is no change to the forecast revenue from CZM of A$1.5m for the financial year ending 30 June 2019 (FY19) which was provided in the Directors Report forming part of the Optiscan 2018 Annual Report.

Corporate Enquiries:

Darren Lurie
Executive Chairman – Optiscan Imaging Limited
E: dlurie@optiscan.com

About Optiscan
Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging and related technologies for medical and research markets.